-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

Introducing Blenrep (belantamab mafodotin-blmf) for Injection, for Intravenous Use

Program: Product Theaters
Session: Introducing BLENREP (belantamab mafodotin-blmf) for Injection, for Intravenous Use
Saturday, December 5, 2020, 11:00 AM-12:00 PM

Allison Doherty

GSK, Collegeville, PA

Disclosures: No relevant conflicts of interest to declare.

See more of: Introducing BLENREP (belantamab mafodotin-blmf) for Injection, for Intravenous Use
See more of: Product Theaters